Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia-Reference-Cited by-同舟云学术

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Published:2020-09 Issue:10255 Volume:396 Page:887-897
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Logunov Denis Y,Dolzhikova Inna V,Zubkova Olga V,Tukhvatulin Amir I,Shcheblyakov Dmitry V,Dzharullaeva Alina S,Grousova Daria M,Erokhova Alina S,Kovyrshina Anna V,Botikov Andrei G,Izhaeva Fatima M,Popova Olga,Ozharovskaya Tatiana A,Esmagambetov Ilias B,Favorskaya Irina A,Zrelkin Denis I,Voronina Daria V,Shcherbinin Dmitry N,Semikhin Alexander S,Simakova Yana V,Tokarskaya Elizaveta A,Lubenets Nadezhda L,Egorova Daria A,Shmarov Maksim M,Nikitenko Natalia A,Morozova Lola F,Smolyarchuk Elena A,Kryukov Evgeny V,Babira Vladimir F,Borisevich Sergei V,Naroditsky Boris S,Gintsburg Alexander L

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Structure analysis of the receptor binding of 2019-nCoV;Chen;Biochem Biophys Res Commun,2020

2. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target;Zhang;Intensive Care Med,2020

3. SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy;Datta;Theranostics,2020

4. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response;Astuti;Diabetes Metab Syndr,2020

5. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion;Xia;Cell Res,2020

Cited by 831 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

2. Immunomics in one health: understanding the human, animal, and environmental aspects of COVID-19;Frontiers in Immunology;2024-09-04

3. Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges;ACS Nano;2024-08-26

4. Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates;Vaccines;2024-08-02

5. Recombinant vaccines: Current updates and future prospects;Asian Pacific Journal of Tropical Medicine;2024-08